Healthcare, Science and Tech

A Tale of Two Food Additives

Food Supplement Bottle, orginally uploaded by ertessplastic

Over the last couple weeks, the New York Times has put out two articles on “food additives” that offer, I think, an interesting case study for what works and what doesn’t in what will likely be a growing field.

In the first, “Magical or Overrated? A Food Additive in a Swirl,” Gary Rivlin addresses Martek Biosciences, a venture-backed entity that has experimented with and marketed various forms of omega-3 fatty acid supplementation. The company has seen success selling the additive to infant formulation companies but has faced challenges in gaining broader adoption. And the question is: “Why?” Well, management suggests that food manufacturers are slow to act:

‘The food and drink industry does not adapt quickly,” said Martek’s president, David M. Abramson. The industry average for testing a product before releasing it on the market, he said, is 2.1 years.

And apparently omega-3 adoption in infant formularies took 10. In the venture business, the way a company’s customer base behaves can often make or break its success given an investment horizon (typically five years). Martek’s dilemma here is interesting in that the industry operatives with which Martek must partner may be slow to act but consumers are also misinformed, and therefore, less than ideal end customers. Specifically, as someone who has done a fair bit of self-education on the nutrition front (a gaping void in our educational system as far as I’m concerned), I know that not all fat is bad fat and eating fat doesn’t necessarily make one fat. But most Americans aren’t there, the ones that are are not looking for “additives,” and the rest may not be interested for another 5-10 years. That’s a problem.

Eight days after the Martek piece, the Times published, “In Live Bacteria, Food Makers See A New Bonanza” by Andrew Martin and Christopher Maag. This one covers the rise of Dannon’s new “live bacteria” yogurt which surpassed the $100 million sales mark in its first year, a rare feat for newly introduced foods. Much like Martek’s omega-3’s, the benefits of such probiotics are up for debate, but somehow “gut regulation” has won where “heart health” (or a host of other omega-3 benefits) has lost. Dannon’s in-house R&D, production, and marketing may certainly have helped, but I bet the hurdle to gain adoption via enhancement of an existing role (yogurt is generally seen as gut friendly) is a lot lower than attempting to sell calorie-counting Kellogg’s consumers that a special type of fat additive on their cereal is health-building. Anyway, fascinating stuff.

If you’re interested in the topic from an investment standpoint, Great Spirit Ventures seems to have a relevant portfolio.

2 Comments

speak up

Add your comment below, or trackback from your own site.

Subscribe to these comments.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

*Required Fields